Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.57 |
| ▸ | TBXAS1 | P24557 | 10/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800484 | 0.82 | CYP3A4 (0.58) | CYP1A2CYP3A4CYP2C9L3MBTL1 | |
| SCHEMBL3078983 | 0.80 | NAPRT (0.62) | NAPRTTBXAS1LMNACYP1A2CYP3A4 | |
| SCHEMBL3078989 | 0.80 | NAPRT (0.62) | NAPRTTBXAS1LMNACYP1A2CYP3A4 | |
| SCHEMBL11844976 | 0.77 | NAPRT (0.54) | NAPRTTBXAS1LMNACYP1A2CYP3A4 | |
| SCHEMBL11844984 | 0.77 | NAPRT (0.54) | NAPRTTBXAS1LMNACYP1A2CYP3A4 | |
| SCHEMBL888708 | 0.74 | NAPRT (0.62) | NAPRTTBXAS1LMNACYP1A2CYP3A4 | |
| SCHEMBL800118 | 0.74 | CA2 (0.52) | LMNACYP3A4CYP2C9ESR1 | |
| SCHEMBL5310336 | 0.74 | NAPRT (0.72) | NAPRTTBXAS1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL10193626 | 0.73 | NAPRT (0.57) | NAPRTTBXAS1LMNACYP1A2CYP3A4 | |
| SCHEMBL48609 | 0.73 | NAPRT (1.00) | NAPRTTBXAS1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | MEIJI SEIKA KAISHA (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9260375-B2 | Metallo-β-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-9115079-B2 | NDM inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-08-25 | — | — | US | disclosed |
| US-20140221330-A1 | NDM INHIBITOR | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | CHIKAUCHI KEN (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ME1, MGAM, GAA | NAPRT 1807/4885TBXAS1 3557/4885LMNA 1246/4885 |
| US-20140221330-A1 | NDM INHIBITOR | MGAM, NQO1, NQO2 | NAPRT 681/4885TBXAS1 4297/4885LMNA 1395/4885 |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | ME1, MGAM, MANBA | NAPRT 1751/4885TBXAS1 3289/4885LMNA 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.